|Efficacy and Safety of Neoadjuvant Intensity-Modulated Radiotherapy With Concurrent Capecitabine for Locally Advanced Rectal Cancer|
|Wang, Lin1; Li, Zi-Yu2; Li, Zhong-Wu3; Li, Yong-Heng4; Sun, Ying-Shi5; Ji, Jia-Fu2; Gu, Jin1; Cai, Yong4|
|关键词||Intensity-modulated radiotherapy Rectal cancer Neoadjuvant Toxicity Complication|
|刊名||DISEASES OF THE COLON & RECTUM|
|WOS标题词||Science & Technology|
|类目[WOS]||Gastroenterology & Hepatology ; Surgery|
|研究领域[WOS]||Gastroenterology & Hepatology ; Surgery|
|关键词[WOS]||TOTAL MESORECTAL EXCISION ; COMBINED-MODALITY THERAPY ; PHASE-III TRIAL ; PREOPERATIVE RADIOTHERAPY ; SURGICAL COMPLICATIONS ; CONFORMAL RADIOTHERAPY ; ORAL CAPECITABINE ; CHEMORADIOTHERAPY ; OXALIPLATIN ; CARCINOMA|
BACKGROUND: We previously conducted a prospective phase II clinical trial studying a unique 22-fraction neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine treatment followed by total mesorectal excision for locally advanced rectal cancer.
OBJECTIVE: The objective of this study was to retrospectively review the efficacy, toxicity, and surgical complications following intensity-modulated radiotherapy in patients who have rectal cancer.
DESIGN: This was a retrospective study.
SETTING: Data were gathered from a surgical database.
PATIENTS: This study included patients who underwent intensity-modulated radiotherapy with gross tumor volume/clinical target volume of 50.6/41.8 Gy in 22 fractions with concurrent capecitabine treatment over a period of 30 days, after which the patients underwent surgery for rectal cancer in Peking University Cancer Hospital (2007-2013).
MAIN OUTCOME MEASURES: The primary end points were acute toxicity, postoperative complications, and complete response rate.
RESULTS: A total of 260 patients were included in our analysis. The median age was 55 years (range, 21-87 years), and 68.5% of the patients were male. The yield complete response rate was 18.5% (48/260). There were no grade 4 toxicity and perioperative mortality. The grade 3 toxicity rate was 5.8%, which included diarrhea (4.2%), neutropenia (1.2%), and radiation dermatitis (0.4%). The 30-day postoperative and severe complication (>= grade 3) rates were 23.1% and 2.7%. The anastomotic leakage rate was 3.3% (5/152). Perineal wound complications (29.2%, 28/96) represented the most common problem following abdominoperineal resection. The estimated 3-year local recurrence-free survival, cancer-specific survival, and disease-free survival rates were 94.2% (95% CI, 90.1%98.3%), 92.2% (95% CI, 87.5%-97.0%), and 81.4% (95% CI, 75.4%-87.4%).
LIMITATION: The retrospective nature and the single-arm design was the limitation of the study.
CONCLUSION: The 22-fraction neoadjuvant intensity-modulated radiotherapy regimen used to treat rectal cancer in this study has a high efficacy rate and a low
|项目编号||Z111107058811021 ; ZY201410|
|资助机构||Beijing Municipal Science & ; Technology Commission ; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support|
|作者单位||1.Peking Univ Canc Hosp, Dept Colorectal Surg, Beijing, Peoples R China|
2.Peking Univ Canc Hosp, Dept Pathol, Beijing, Peoples R China
3.Peking Univ Canc Hosp, Dept Radiat Oncol, Beijing, Peoples R China
4.Peking Univ Canc Hosp, Dept Radiol, Beijing, Peoples R China
5.Peking Univ Canc Hosp, Dept Gastrointestinal Surg, Beijing, Peoples R China
|Wang, Lin,Li, Zi-Yu,Li, Zhong-Wu,et al. Efficacy and Safety of Neoadjuvant Intensity-Modulated Radiotherapy With Concurrent Capecitabine for Locally Advanced Rectal Cancer[J]. DISEASES OF THE COLON & RECTUM,2015,58(2):186-192.|
|APA||Wang, Lin.,Li, Zi-Yu.,Li, Zhong-Wu.,Li, Yong-Heng.,Sun, Ying-Shi.,...&Cai, Yong.(2015).Efficacy and Safety of Neoadjuvant Intensity-Modulated Radiotherapy With Concurrent Capecitabine for Locally Advanced Rectal Cancer.DISEASES OF THE COLON & RECTUM,58(2),186-192.|
|MLA||Wang, Lin,et al."Efficacy and Safety of Neoadjuvant Intensity-Modulated Radiotherapy With Concurrent Capecitabine for Locally Advanced Rectal Cancer".DISEASES OF THE COLON & RECTUM 58.2(2015):186-192.|